From Innovation to Acquisition: CrossBridge Bio’s ADC Journey

As investment, innovation, and dealmaking continue to reshape the antibody-drug conjugate (ADC) landscape, Michael Torres, Chief Executive Officer of CrossBridge Bio, has shared his perspective on the scientific and strategic trends set to define the next generation of ADC development.

In a recent interview, Torres reflected on the evolution of the field following Eli Lilly’s acquisition of CrossBridge Bio, discussing the growing interest in dual-payload ADCs, the importance of intelligent payload selection, and emerging approaches to overcoming treatment resistance. He also highlighted how the ADC partnership landscape is maturing, with future success increasingly dependent on programs built around strong biological rationale rather than novelty alone.

Commenting on the role of industry collaboration and scientific exchange, Torres noted:

“World ADC San Diego helped increase visibility for the program and provided a useful forum to share key elements of the dataset. That visibility supported ongoing discussions and ultimately contributed to the Lilly transaction.”

His comments underscore the continued importance of forums that bring together ADC developers, biopharma leaders, investors, technology innovators, and solution providers to share data, foster partnerships, and accelerate development.

As the ADC field enters a new era of growth and competition, the themes explored by Torres are expected to take centre stage at the 17th World ADC San Diego Summit (12-15 October 2026). The event will unite the global ADC community to discuss the latest clinical advances, next-generation technologies, translational research, manufacturing strategies, and business development opportunities shaping the future of the sector.

For organisations developing differentiated ADC therapies, evaluating partnership opportunities, or seeking insight into where the field is heading, Torres’ interview provides a valuable perspective on the scientific, commercial, and dealmaking dynamics driving innovation across the industry.

Read the full interview:
https://ter.li/ydjy3e8h

Learn more about the 17th World ADC San Diego Summit:
https://ter.li/u93bnj0q

Media Contact
Kate Woodford
Marketing Manager
17th World ADC San Diego Summit
Hanson Wade

About the 17th World ADC San Diego Summit
The 17th World ADC San Diego Summit is the definitive global meeting place for the antibody-drug conjugate community, bringing together biopharma leaders, ADC developers, technology providers, and investors to accelerate the development of safer, more effective, and more commercially successful ADC therapies.